

Appendix 1: 3,284 CRUK funded studies were suitable for inclusion. Of these 28 studies (0.9%) did not specify the PIs name and we were unable to ascertain the gender of the named PI in 75 studies (2.3%). 3,181 studies were included in the final CRUK analysis.

Appendix 1a: Number of studies by cancer site.

Cancer site	Excluding CRUK			CRUK		
	Male PIs	Female PIs	Fold difference	Male PIs	Female PIs	Fold difference
All	2890	1296	<b>2.23</b>	2262	919	<b>2.46</b>
Haematological	791	360	<b>2.20</b>	175	39	<b>4.49</b>
Breast	325	235	<b>1.38</b>	166	103	<b>1.61</b>
Colorectal	93	46	<b>2.02</b>	153	43	<b>3.56</b>
Prostate	71	18	<b>3.94</b>	89	32	<b>2.78</b>
Skin	44	42	<b>1.05</b>	45	36	<b>1.25</b>
Lung	42	35	<b>1.20</b>	68	19	<b>3.58</b>
Liver	24	12	<b>2.00</b>	13	4	<b>3.25</b>
Upper GI and oesophageal	23	13	<b>1.77</b>	49	22	<b>2.23</b>
Ovarian	21	25	<b>0.84</b>	77	34	<b>2.26</b>
Mesothelioma	17	10	<b>1.70</b>	11	0	<b>N/A</b>
Head and neck	16	4	<b>4.00</b>	54	13	<b>4.15</b>
Cervical	15	10	<b>1.50</b>	21	22	<b>0.95</b>
Renal	11	8	<b>1.38</b>	32	13	<b>2.46</b>
Brain	9	12	<b>0.75</b>	51	24	<b>2.13</b>
Pancreatic	9	5	<b>1.80</b>	32	6	<b>5.33</b>

Appendix 1B: Number of studies by disease theme.

Disease theme	Excluding CRUK			CRUK		
	Male PIs	Female PIs	Fold difference	Male PIs	Female PIs	Fold difference
All	2890	1296	<b>2.23</b>	2262	919	<b>2.46</b>
Pathogenesis	1714	775	<b>2.21</b>	1192	436	<b>2.73</b>
Drug Therapy	736	336	<b>2.19</b>	692	206	<b>3.36</b>
Diagnostic, Screening and Monitoring	454	201	<b>2.26</b>	257	129	<b>1.99</b>
Women's Health	361	265	<b>1.36</b>	174	113	<b>1.54</b>
Immunology (inc biologics)	304	143	<b>2.13</b>	224	59	<b>3.80</b>
Paediatrics	115	57	<b>2.02</b>	56	34	<b>1.65</b>
Radiotherapy	89	19	<b>4.68</b>	133	68	<b>1.96</b>
Infection-associated	87	40	<b>2.18</b>	39	9	<b>4.33</b>
Men's Health	84	22	<b>3.82</b>	80	36	<b>2.22</b>
Surgery	54	14	<b>3.86</b>	69	21	<b>3.29</b>
Psychosocial	43	66	<b>0.65</b>	45	72	<b>0.63</b>
Occupational Health	14	3	<b>4.67</b>	7	0	<b>N/A</b>
Global Health	7	5	<b>1.40</b>	9	3	<b>3.00</b>
Geriatrics	3	4	<b>0.75</b>	5	3	<b>1.67</b>

Appendix 1C: Number of studies by phase of R&D pipeline.

	Excluding CRUK			CRUK		
Phase of R&D	Male PIs	Female PIs	Fold difference	Male PIs	Female PIs	Fold difference
All	2890	1296	<b>2.23</b>	2262	919	<b>2.46</b>
Pre-clinical	1996	802	<b>2.49</b>	1300	453	<b>2.87</b>
Public health	304	181	<b>1.68</b>	237	191	<b>1.24</b>
Cross-disciplinary	285	146	<b>1.95</b>	229	90	<b>2.54</b>
Phase I-III	182	109	<b>1.67</b>	462	159	<b>2.91</b>
Product development	106	54	<b>1.96</b>	26	25	<b>1.04</b>

Appendix 1D: Number of studies by funding organisation.

	Excluding CRUK			CRUK		
Funding organisation	Male PIs	Female PIs	Fold difference	Male PIs	Female PIs	Fold difference
<b>All</b>	<b>2890</b>	<b>1296</b>	<b>2.23</b>	<b>2262</b>	<b>919</b>	<b>2.46</b>
Charity (excluding Wellcome and CRUK)	1101	585	<b>1.88</b>			
MRC	505	253	<b>2.00</b>			
BBSRC	416	88	<b>4.73</b>			
Department of Health	337	209	<b>1.61</b>			
EPSRC	292	63	<b>4.63</b>			
Wellcome	121	70	<b>1.73</b>			
Other	82	19	<b>4.32</b>			
European Commission (inc ERC)	36	9	<b>4.00</b>			